Formulation and characterization of echogenic lipid-pluronic nanobubbles

Molecular Pharmaceutics

Volumn 7, Issue 1, 2010, Pages 49-59

  Krupka, Tianyi M ^a,b   Solorio, Luis ^b   Wilson, Robin E ^b   Wu, Hanping ^a   Azar, Nami ^a   Exner, Agata A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Case Western Reserve University   (United States)

Author keywords

Lipid; Nanobubbles; Pluronic; Surfactant; Ultrasound contrast agent

Indexed keywords

COPOLYMER; ETHYLENE OXIDE; FLUOROCARBON; LIPID; NANOBUBBLE; POLOXAMER;

ARTICLE; DISSOLUTION; DRUG FORMULATION; HYDRATION; HYDRODYNAMICS; IMAGING; LIPID MEMBRANE; MOLECULAR WEIGHT; PRIORITY JOURNAL; ULTRASOUND;

ANIMALS; COLORECTAL NEOPLASMS; CONTRAST MEDIA; DRUG CARRIERS; DRUG STABILITY; FEMALE; HYDROPHOBICITY; LIPIDS; MICROBUBBLES; PARTICLE SIZE; POLOXAMER; RATS; ULTRASONOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76249123206     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp9001816     Document Type: Article

References (71)

1. Wheatley, M. A.; Schrope, B.; Shen, P. Contrast agents for diagnostic ultrasound: development and evaluation of polymercoated microbubbles. Biomaterials 1990, 11 (9), 713-7.
2. Schneider, M.; et al. BR1: a new ultrasonographic contrast agent based on sulfur hexafluoride-filled microbubbles. Invest. Radiol. 1995, 30 (8), 451-7.
3. Bjerknes, K.; et al. Air-filled polymeric microcapsules from emulsions containing different organic phases. J. Microencapsulation 2001, 18 (2), 159-71.
4. Cavalieri, F.; et al. Stable polymeric microballoons as multifunctional device for biomedical uses: synthesis and characterization. Langmuir 2005, 21 (19), 8758-64.
5. Feinstein, S. B.; et al. Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results. J. Am. Coll. Cardiol. 1990, 16 (2), 316-24.
6. Dayton, P. A.; et al. Optical and acoustical observations of the effects of ultrasound on contrast agents. IEEE Trans. Ultrasonics, Ferroelectr., Freq. Control 1999, 46 (1), 220-32.
7. Ferrara, K. W.; Borden, M. A.; Zhang, H. Lipid-Shelled Vehicles: Engineering for Ultrasound Molecular Imaging and Drug Delivery. Acc. Chem. Res. 2009, 42 (7), 881-92.
8. Unger, E. C.; et al. Therapeutic applications of lipid-coated microbubbles. Adv. Drug Delivery Rev. 2004, 56 (9), 1291-314.
9. Zheng, H.; et al. A sensitive ultrasonic imaging method for targeted contrast microbubble detection. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2008, 2008, 5290-3.
10. Miller, A. P.; Nanda, N. C. Contrast echocardiography: new agents. Ultrasound Med. Biol. 2004, 30 (4), 425-34.
11. Tang, J.; et al. Evaluation of the effect of protamine on human prostate carcinoma PC-3m using contrast enhanced Doppler ultrasound. J. Urol. 2003, 170 (2 Part 1), 611-4.
12. Crowder, K. C.; et al. Sonic activation of molecularly-targeted nanoparticles accelerates transmembrane lipid delivery to cancer cells through contact-mediated mechanisms: implications for enhanced local drug delivery. Ultrasound Med. Biol. 2005, 31 (12), 1693-700.
13. Larina, I. V.; et al. Enhancement of drug delivery in tumors by using interaction of nanoparticles with ultrasound radiation. Technol. Cancer Res. Treat. 2005, 4 (2), 217-26.
14. Chumakova, O. V.; et al. Composition of PLGA and PEI/DNA nanoparticles improves ultrasound-mediated gene delivery in solid tumors in vivo. Cancer Lett. 2008, 261 (2), 215-25.
15. Fang, J. Y.; et al. Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells. Ultrasonics 2009, 49 (1), 39-46.
16. Lindner, J. R.; et al. Microbubble persistence in the microcirculation during ischemia/reperfusion and inflammation is caused by integrin- and complement-mediated adherence to activated leukocytes. Circulation 2000, 101 (6), 668-75.
17. Kheirolomoom, A.; et al. Acoustically-active microbubbles conjugated to liposomes: characterization of a proposed drug delivery vehicle. J. Controlled Release 2007, 118 (3), 275-84.
18. Bekeredjian, R.; et al. Ultrasound-targeted microbubble destruction can repeatedly direct highly specific plasmid expression to the heart. Circulation 2003, 108 (8), 1022-6.
19. Husseini, G. A.; Pitt, W. G. Ultrasonic-activated micellar drug delivery for cancer treatment. J. Pharm. Sci. 2009, 98 (3), 795-811.
20. Rapoport, N.; Gao, Z.; Kennedy, A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J. Natl. Cancer Inst. 2007, 99 (14), 1095-106.
21. Husseini, G. A.; et al. Release of doxorubicin from unstabilized and stabilized micelles under the action of ultrasound. J. Nanosci. Nanotechnol. 2007, 7 (3), 1028-33.
22. Frenkel, V. Ultrasound mediated delivery of drugs and genes to solid tumors. Adv. Drug Delivery Rev. 2008, 60 (10), 1193-208.
23. Lum, A. F.; et al. Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubbles. J. Controlled Release 2006, 111 (1-2), 128-34.
24. Bekeredjian, R.; et al. Augmentation of cardiac protein delivery using ultrasound targeted microbubble destruction. Ultrasound Med. Biol. 2005, 31 (5), 687-91.
25. Gao, Z.; Fain, H. D.; Rapoport, N. Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers. Mol. Pharmaceutics 2004, 1 (4), 317-30.
26. Ferrara, K. W.; Borden, M. A.; Zhang, H. Lipid-shelled vehicles: engineering for ultrasound molecular imaging and drug delivery. Acc. Chem. Res. 2009, 42 (7), 881-92.
27. Goertz, D. E.; et al. High-frequency, nonlinear flow imaging of microbubble contrast agents. IEEE Trans. Ultrasonics, Ferroelectr., Freq. Control 2005, 52 (3), 495-502.
28. Zong, Y.; et al. Optimal design and experimental investigation of surfactant encapsulated microbubbles. Ultrasonics 2006, 44 (Suppl. 1), e119-22.
29. Hwang, T. L.; et al. Development and evaluation of perfluorocarbon nanobubbles for apomorphine delivery. J. Pharm. Sci. 2009, 98 (10), 3735-47.
30. Ivanova, R.; Lindman, B.; Alexandridis, P. Effect of pharmaceutically acceptable glycols on the stability of the liquid crystalline gels formed by Poloxamer 407 in water. J. Colloid Interface Sci. 2002, 252 (1), 226-35.
31. Sakai, T.; Alexandridis, P. Single-step synthesis and stabilization of metal nanoparticles in aqueous pluronic block copolymer solutions at ambient temperature. Langmuir 2004, 20 (20), 8426-30.
32. Sakai, T.; Alexandridis, P. Spontaneous formation of gold nanoparticles in poly(ethylene oxide)-poly(propylene oxide) solutions: solvent quality and polymer structure effects. Langmuir 2005, 21 (17), 8019-25.
33. Tharmalingam, T.; et al. Pluronic enhances the robustness and reduces the cell attachment of mammalian cells. Mol. Biotechnol. 2008, 39 (2), 167-77.
34. Michaels, J. D.; et al. Interfacial properties of cell culture media with cell-protecting additives. Biotechnol. Bioeng. 1995, 47 (4), 420-30.
35. Michaels, J. D.; et al. Analysis of cell-to-bubble attachment in sparged bioreactors in the presence of cell-protecting additives. Biotechnol. Bioeng. 1995, 47 (4), 407-19.
36. Schmolka, I. R. Theory of emulsions. Fed. Proc. 1970, 29 (5), 1717-20.
37. Schmolka, I. R. Artificial blood emulsifiers. Fed. Proc. 1975, 34 (6), 1449-53.
38. Spitzenberger, T. J.; et al. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J. Cereb. Blood Flow Metab. 2007, 27 (5), 1033-42.
39. Alakhov, V.; et al. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjugate Chem. 1996, 7 (2), 209-16.
40. Batrakova, E. V.; et al. Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells. Pharm. Res. 1998, 15 (10), 1525-32.
41. Batrakova, E. V.; et al. Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm. Res. 2003, 20 (10), 1581-90.
42. Kabanov, A. V.; Batrakova, E. V.; Miller, D. W. Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv. Drug Delivery Rev. 2003, 55 (1), 151-64.
43. Krupka, T. M.; et al. Effect of intratumoral injection of carboplatin combined with pluronic P85 or L61 on experimental colorectal carcinoma in rats. Exp. Biol. Med. (Maywood) 2007, 232 (7), 950-7.
44. Krupka, T. M.; et al. Injectable polymer depot combined with radiofrequency ablation for treatment of experimental carcinoma in rat. Invest. Radiol. 2006, 41 (12), 890-7.
45. Minko, T.; et al. Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J. Controlled Release 2005, 105 (3), 269-78.
46. Venne, A.; et al. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 1996, 56 (16), 3626-9.
47. Weinberg, B. D.; et al. Combination of sensitizing pretreatment and radiofrequency tumor ablation: evaluation in rat model. Radiology 2008, 246 (3), 796-803.
48. Krupka, T. M.; Dremann, D.; Exner, A. A. Time and dose dependence of pluronic bioactivity in hyperthermia-induced tumor cell death. Exp. Biol. Med. (Maywood) 2009, 234 (1), 95-104.
49. Kamiyama, N. Update of ultrasound contrast imaging. Int. Congr. Ser. 2004, 1274, 53-56.
50. Linden, R. A.; et al. Contrast enhanced ultrasound flash replenishment method for directed prostate biopsies. J. Urol. 2007, 178 (6), 2354-8.
51. Hotta, N.; et al. Advanced dynamic flow imaging with contrastenhanced ultrasonography for the evaluation of tumor vascularity in liver tumors. Clin. Imaging 2005, 29 (1), 34-41.
52. Kirby, B. J.; Hasselbrink, E. F., Jr. Zeta potential of microfluidic substrates: 1. Theory, experimental techniques, and effects on separations. Electrophoresis 2004, 25 (2), 187-202.
53. Korpanty, G.; et al. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin. Cancer Res. 2007, 13 (1), 323-30.
54. Heckemann, R. A.; et al. Liver lesions: intermittent second-harmonic gray-scale US can increase conspicuity with microbubble contrast material-early experience. Radiology 2000, 216 (2), 592-6.
55. Lai, J. I.; et al. Controlling the size of magnetic nanoparticles using pluronic block copolymer surfactants. J. Phys. Chem. B 2005, 109 (1), 15-8.
56. Niesz, K.; Grass, M.; Somorjai, G. A. Precise control of the Pt nanoparticle size by seeded growth using EO13PO30EO13 triblock copolymers as protective agents. Nano Lett. 2005, 5 (11), 2238-40.
57. Frey, S. L.; Lee, K. Y. Temperature dependence of poloxamer insertion into and squeeze-out from lipid monolayers. Langmuir 2007, 23 (5), 2631-7.
58. Wu, G.; Lee, K. Y. Effects of poloxamer 188 on phospholipid monolayer morphology: an atomic force microscopy study. Langmuir 2009, 25 (4), 2133-9.
59. Frey, S. L.; et al. Effects of block copolymer's architecture on its association with lipid membranes: experiments and simulations. J. Chem. Phys. 2007, 127 (11), 114904.
60. Chang, L. C.; et al. Interactions of Pluronics with phospholipid monolayers at the air-water interface. J. Colloid Interface Sci. 2005, 285 (2), 640-52.
61. Chen, Y. C.; et al. Pluronic block copolymers: novel functions in ultrasound-mediated gene transfer and against cell damage. Ultrasound Med. Biol. 2006, 32 (1), 131-7.
62. Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53 (2), 283-318.
63. Decuzzi, P.; et al. Intravascular delivery of particulate systems: does geometry really matter? Pharm. Res. 2009, 26 (1), 235-43.
64. Batrakova, E. V.; et al. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. 2001, 299 (2), 483-93.
65. Zhirnov, A. E.; et al. Lipid composition determines interaction of liposome membranes with Pluronic L61. Biochim. Biophys. Acta 2005, 1720 (1-2), 73-83.
66. Batrakova, E. V.; et al. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther. 2003, 304 (2), 845-54.
67. Inoue, T. Vesicles, 1st ed.; Surfactant science series; Rosoff, M., Ed.; Marcel Dekker, Inc.: New York, NY, 1996; Vol. 62, p 752.
68. Santore, M. M.; et al. Effect of Surfactant on Unilamellar Polymeric Vesicles: Altered Membrane Properties and Stability in the Limit of Weak Surfactant Partitioning. Langmuir 2002, 18, 7299-7308.
69. Frinking, P. J.; de Jong, N. Acoustic modeling of shell-encapsulated gas bubbles. Ultrasound Med. Biol. 1998, 24 (4), 523-33.
70. Bouakaz, A.; et al. Noninvasive measurement of the hydrostatic pressure in a fluid-filled cavity based on the disappearance time of micrometer-sized free gas bubbles. Ultrasound Med. Biol. 1999, 25 (9), 1407-15.
71. Samaddar, S. K.; De, J. N.; Sperber, D. Realistic estimate of incomplete fusion excitation function in nucleus-nucleus collisions. Phys. Rev. C: Nucl. Phys. 1992, 46 (6), 2631-4.